{
    "clinical_study": {
        "@rank": "151527", 
        "acronym": "CONTACT-SPE", 
        "arm_group": [
            {
                "arm_group_label": "Actilyse", 
                "arm_group_type": "Active Comparator", 
                "description": "Thrombolytic therapy: Patients treated with initial thrombolytic therapy (Actilyse) followed with anticoagulant therapy (unfractionated/low-molecular weight heparin)."
            }, 
            {
                "arm_group_label": "UHF/LMWH", 
                "arm_group_type": "Active Comparator", 
                "description": "Anticoagulation therapy: Patients treated with anticoagulation therapy only (unfractionated/low-molecular weight heparin)."
            }
        ], 
        "brief_summary": {
            "textblock": "Currently there is no clear guidance for the treatment of moderate risk of pulmonary\n      embolism. The aim of the study is to compare two different therapeutic modalities - standard\n      anticoagulation versus thrombolytic treatment followed by anticoagulation in standard\n      regimen as stated in the pulmonary embolism guidelines."
        }, 
        "brief_title": "Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism", 
        "completion_date": {
            "#text": "December 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Pulmonary Embolism", 
        "condition_browse": {
            "mesh_term": [
                "Embolism", 
                "Hypertension, Pulmonary", 
                "Pulmonary Embolism"
            ]
        }, 
        "detailed_description": {
            "textblock": "Standard treatment of moderate risk pulmonary embolism constitutes of sole anticoagulation\n      therapy. In case of troponin positivity and/or echocardiographic findings as i.e. thrombi in\n      RV thrombolytic therapy should be considered. The aim of this trial is to compare the two\n      treatment modalities in their ability to reduce/predict 12 month end-point: pulmonary\n      hypertension, right ventricular failure, exercise capacity."
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  moderate risk pulmonary embolism as defined by the European Society of Cardiology\n             /ESC/ guidelines\n\n          -  signed informed consent\n\n        Exclusion Criteria:\n\n          -  patient not willing to sigh informed consent\n\n          -  absolute contraindication of thrombolysis\n\n          -  inability to obtain meaningfull echocardiographic images\u00a8\n\n          -  pulmonary arterial hypertension\n\n          -  known right ventricular failure"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "100", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 28, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02132689", 
            "org_study_id": "FNO-KVO-3"
        }, 
        "intervention": [
            {
                "arm_group_label": "Actilyse", 
                "intervention_name": "Actilyse (Thrombolytic therapy)", 
                "intervention_type": "Drug", 
                "other_name": "Actilyse"
            }, 
            {
                "arm_group_label": [
                    "Actilyse", 
                    "UHF/LMWH"
                ], 
                "intervention_name": "Heparine (Standard anticoagulation therapy)", 
                "intervention_type": "Drug", 
                "other_name": "unfractionated/low-molecular weight heparine"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Fibrinolytic Agents", 
                "Heparin, Low-Molecular-Weight", 
                "Tissue Plasminogen Activator"
            ]
        }, 
        "is_fda_regulated": "No", 
        "keyword": "Moderate Risk Acute Pulmonary Embolism", 
        "lastchanged_date": "May 6, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Opava", 
                        "country": "Czech Republic", 
                        "zip": "746 01"
                    }, 
                    "name": "Silesian Hospital Opava"
                }, 
                "status": "Completed"
            }, 
            {
                "contact": {
                    "email": "vaclav.prochazka@fno.cz", 
                    "last_name": "Vaclav Prochazka, MD, PhD, MSc", 
                    "phone": "0042597372544"
                }, 
                "contact_backup": {
                    "email": "jiri.hyncica@fno.cz", 
                    "last_name": "Jiri Hyncica", 
                    "phone": "00420597372587"
                }, 
                "facility": {
                    "address": {
                        "city": "Ostrava-Poruba", 
                        "country": "Czech Republic", 
                        "zip": "708 52"
                    }, 
                    "name": "University Hospital Ostrava"
                }, 
                "investigator": [
                    {
                        "last_name": "Radovan Stancik, MD", 
                        "role": "Principal Investigator"
                    }, 
                    {
                        "last_name": "Jan Mrozek, MD", 
                        "role": "Sub-Investigator"
                    }
                ], 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "Czech Republic"
        }, 
        "number_of_arms": "2", 
        "official_title": "Comparison of Thrombgolytic and Anticoagulation Therapy in Submassive Pulmonary Embolism in Context of Pulmonary Hypertension, Right Heart Failure and Patient Functional Ability", 
        "overall_contact": {
            "email": "vaclav.prochazka@fno.cz", 
            "last_name": "Vaclav Prochazka, MD, PhD, MSc", 
            "phone": "00420597372544"
        }, 
        "overall_contact_backup": {
            "email": "jiri.hyncica@fno.cz", 
            "last_name": "Jiri Hyncica", 
            "phone": "00420597372587"
        }, 
        "overall_official": {
            "affiliation": "Department of Cardiology, University Hospital Ostrava", 
            "last_name": "Radovan Stancik, MD", 
            "role": "Principal Investigator"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "Czech Republic: Ethics Committee", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 4", 
        "primary_completion_date": {
            "#text": "May 2014", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "description": "The primary outcome of the study is to follow clinical manifestations of right ventricular failure (assessed according to the New York Heart Association /NYHA/ classification).", 
                "measure": "Clinical manifestations of right ventricular failure and pulmonary hypertension and cardiovascular-related death", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The primary outcome of the study is to follow pulmonary hypertension (measured in mmHg).", 
                "measure": "Pulmonary hypertension", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }, 
            {
                "description": "The primary outcome of the study is to follow the number of cardiovascular-related deaths within the time frame of 12 months.", 
                "measure": "Cardiovascular-related deaths", 
                "safety_issue": "No", 
                "time_frame": "12 months"
            }
        ], 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02132689"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "description": "The secondary outcome measure of the study is to follow echocardiographic manifestations of right ventricular failure (TdiSm).", 
            "measure": "Echocardiographic manifestations of right ventricular failure and pulmonary hypertension.", 
            "safety_issue": "No", 
            "time_frame": "12 months"
        }, 
        "source": "University Hospital Ostrava", 
        "sponsors": {
            "collaborator": [
                {
                    "agency": "Municipal Hospital Ostrava Fifejdy", 
                    "agency_class": "Other"
                }, 
                {
                    "agency": "Silesian Hospital Opava", 
                    "agency_class": "Other"
                }
            ], 
            "lead_sponsor": {
                "agency": "University Hospital Ostrava", 
                "agency_class": "Other"
            }
        }, 
        "start_date": "March 2011", 
        "study_design": "Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}